children (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). Also, treatment failure on anticholinergics alone was more likely than when anticholinergics were combined with beta 2 -agonists from four trials on 173 children (OR 2.65; 95% CI 1.2 to 5.88). Data on clinical scores/symptoms that were measured on different scales were conflicting. Individual trials reported that lung function was superior in the combination group when compared with anticholinergic agents used alone. The use of anticholinergics was not found to be associated with significant side effects.
Authors' conclusions
In children over the age of two years with acute asthma exacerbations, inhaled anticholinergics as single agent bronchodilators were less efficacious than beta 2 -agonists. Inhaled anticholinergics were also less efficacious than inhaled anticholinergics combined with beta 2 -agonists. Inhaled anticholinergic drugs alone are not appropriate for use as a single agent in children with acute asthma exacerbations.
P L A I N L A N G U A G E S U M M A R Y

Anticholinergic therapy for acute asthma in children
Asthma is a condition that affects the airways (tubes carrying air in and out of the lungs). During an asthma exacerbation (attack), the airways narrow and drugs can be taken to dilate, or widen, the airways. Common bronchodilators (medicines used to widen the airways) are short-acting beta 2 -agonists (e.g. salbutamol) or anticholinergics (e.g. ipratropium bromide). In this review, we examined if the use of anticholinergic inhalers during an asthma attack in children aged over two years is effective compared to either placebo or another bronchodilator. We also looked at combinations of anticholinergic plus a beta 2 -agonist compared to an anticholinergic on its own.
We found six small trials of unclear quality answering these two questions. We found data from four trials on 171 children comparing anticholinergics with beta 2 -agonists. Children on anticholinergics alone were significantly more likely to experience treatment failure than those on beta 2 -agonists (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). We also found data from four trials on 173 children comparing children on anticholinergics alone with children on anticholinergics plus beta 2 -agonists. In this case, treatment failure was more likely in children taking anticholinergics only than if they were combined with beta 2 -agonists (OR 2.65; 95% CI 1.2 to 5.88). We were only able to combine data for treatment failure and hospitalisation.
In summary, we found that inhaled anticholinergics used on their own are less effective than inhaled beta 2 -agonists used alone or in combination with anticholinergics. Inhaled anticholinergics seem safe, with no significant side effects apparent.
B A C K G R O U N D
Inhaled anticholinergics as single agent bronchodilators (or in combination with beta 2 -agonists) are one of the several medications available for the treatment of acute asthma in children. Ipratropium bromide, an inhaled anticholinergic agent, has been used extensively in emergency departments as adjunctive therapy with beta 2 -agonists for the emergency treatment of acute asthma exacerbations. The objective of this review was to determine the effectiveness of only inhaled anticholinergic drugs (i.e. administered alone), compared to a control or combination treatment in children over the age of two years with acute asthma.
Description of the condition
Asthma is an inflammatory disorder of the airways in which many cells and cellular elements play a role. In susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment. The inflammation also causes an associated increase in the existing bronchial hyperresponsiveness to a variety of stimuli (NHLBI 2007) . Airflow obstruction (excessive airway narrowing) in asthma is the result of contraction of the airway smooth muscle and swelling of the airway wall due to smooth muscle hypertrophy and hyperplasia, inflammatory cell infiltration, oedema, goblet cell and mucous gland hyperplasia, mucous hypersecretion, protein deposition in-cluding collagen and epithelial desquamation. Potential triggers for the inflammatory process in asthma include allergy, viral respiratory infections, irritants such as tobacco smoke, air pollutants and occupational dusts, gases and chemicals, certain drugs, and non-specific stimuli such as cold air exposure and exercise (NAC 2006) .
Description of the intervention
Inhaled anticholinergics are bronchodilators. Ipratropium bromide is the most studied anticholinergic bronchodilator, and now most widely used of anticholinergic agents. Ipratropium bromide has been used extensively in emergency departments as adjunctive therapy with beta 2 -agonists for the emergency treatment of acute asthma exacerbations. Multiple doses of anticholinergics in combination with beta 2 -adrenergic agents have shown to be beneficial in adults (Undem 2001) and of some merit in school-aged children with severe asthma exacerbation (Plotnick 2008). Current guidelines recommend the use of a combination of inhaled beta 2 -agonists and anticholinergics, particularly for patients with acute severe or life-threatening asthma in the emergency setting. Anticholinergics tend not to be used as first-line drugs for asthma exacerbation (Gross 1988) . Inhaled anticholinergics are the drugs of choice in bronchospasm provoked by psychogenic stimuli and beta 2 -blockers (Gross 1988; Beakes 1997). Ipratropium bromide also appears to have some benefit in nocturnal asthma (Beakes 1997). However, the principal clinical use of ipratropium bromide is in the treatment of adult patients with chronic obstructive pulmonary disease (Brown 2001) .
How the intervention might work
Airway calibre is controlled in health and disease by many influences. The parasympathetic nervous system is one among the many mechanisms, which regulates the airway calibre by varying the bronchomotor tone. Muscarinic receptors are widely distributed in the airways and the release of acetylcholine at these sites results in both smooth muscle contraction and release of secretions from submucosal glands. An opportunity for therapeutic intervention exists at the level of these muscarinic receptors. Anticholinergics such as atropine and its analogues are competitive inhibitors of acetylcholine and may result in bronchodilatation by reducing the tone of smooth muscles (Gross 1988). Anticholinergic agents act at muscarinic receptors, competitively inhibiting the effects of acetylcholine. Acetylcholine acts by causing smooth muscle constriction, which provides bronchomotor tone. By antagonising the effects of acetylcholine, cholinergic bronchomotor tone is inhibited and the vagal reflexes that mediate bronchoconstriction are blocked (McDonald 2010) . Cholinergic-induced bronchoconstriction appears to involve primarily the large airways, whereas beta 2 -agonist medications relax both large and small airway constriction equally (Rodrigo 2002) . Ipratropium bromide (8-isopropyl-noratropine-methobromide) is a synthetic quaternary ammonium congener of atropine. Ipratropium bromide differs from atropine and other naturally occurring anticholinergic alkaloids in one major aspect -it is insoluble in lipids (although freely soluble in water) and crosses biological barriers with difficulty. One could thus describe ipratropium bromide as a topical form of atropine and hence virtually free of systemic side effects. Neither atropine nor ipratropium bromide is selective for the subtypes of muscarinic receptors. It was the first anticholinergic agent to be approved for use as a bronchodilator in adults and children (for acute asthma in children), with a wide therapeutic margin of safety and has no important side effects (Gross 1988; Brown 2001) . Ipratropium bromide is a less potent bronchodilator than beta 2 -adrenergic agents. The onset of action of ipratropium is slower than short-acting beta 2 -adrenergic agents (30 to 90 minutes versus 5 to 15 minutes).
Why it is important to do this review
The role of anticholinergic drugs for wheezing in children under the age of two years has been reviewed (Everard 2005). The authors concluded that there is not enough support for the uncritical use of anticholinergic therapy for wheezing under the age of two years. The review by Plotnick et al focused specifically on combined treatment with anticholinergics and beta 2 -agonists in asthmatic children over the age of two years and concluded that anticholinergics plus beta 2 -agonists have a beneficial effect over beta 2 -agonists alone in improving lung function significantly and the addition of multiple doses of anticholinergics to beta 2 -agonists reduced the risk of hospital admissions in children with predominantly severe exacerbations (Plotnick 2008). Plotnick et al also found that there was no conclusive evidence for using multiple doses of anticholinergics in children with mild or moderate asthma exacerbations. There is good evidence for the safety and efficacy of frequent doses of ipratropium bromide (every 20 to 30 minutes) used in addition to beta 2 -agonists for the first two hours of a severe asthma attack in children over two years (BTS 2009 ). The addition of ipratropium bromide to beta 2 -agonists for severe acute asthma may lead to some improvement in clinical symptoms and reduce the need for more intensive treatment in children less than two years. It does not significantly reduce the length of hospital stay either in combination with beta 2 -agonists or in comparison with placebo (Everard 2005; BTS 2009). When investigating the therapeutic effect of an agent that may be used in combination with another agent, it is important to establish separately the effectiveness of both the agents over placebo. It is also essential to compare the beneficial effect of the combined agents over placebo as well as the individual agents. In this way it is possible to establish: a) if the single agents have a therapeutic effect; and b) if there is an additive or synergistic effect from combining the agents. This review focuses on the effectiveness of anticholinergic drugs (without beta 2 -agonists) in children aged over two years with acute asthma. By comparing the effect of anticholinergics as single agents with that of other single agents and with combined therapy (anticholinergics with beta 2 -agonists) as reviewed previously (Plotnick 2008), we aim to establish the role of anticholinergics as a monotherapy in the treatment of children over two years of age with acute asthma.
O B J E C T I V E S
To determine the effectiveness of inhaled anticholinergic drugs (used alone) compared to a control or combination treatment in children over the age of two years with acute asthma.
M E T H O D S Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) in which only inhaled anticholinergics were given compared with placebo, or any other drug, or drug combinations for children over the age of two years with acute asthma.
Types of participants
We included trials of children aged two to eighteen years with acute asthma in all settings (emergency room, observation unit, in-patient, out-patient, general practice and home). Asthma must have been physician diagnosed or must have satisfied the criteria established internationally (such as BTS 2009 guidelines). We excluded studies involving children under the age of two years since difficulties arise in establishing the diagnosis of asthma unequivocally. Also they have been reviewed previously (Everard 2005).
Types of interventions
Inhaled anticholinergic drugs delivered by any means; nebulised or by metered dose inhalers with or without spacer devices, and with or without facemask. We included all doses and dosing regimens. We included the following comparisons.
1. Anticholinergics versus placebo. 2. Anticholinergics versus beta 2 -agonists.
3. Anticholinergics versus anticholinergics plus beta 2 -agonists. 4. Anticholinergics versus any other drugs or drug combinations.
Types of outcome measures
Outcome measures in the studies are summarised in Table 1 
Search methods for identification of studies
The methods used to identify the studies are summarised below.
Electronic searches
We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see Appendix 1 for further details). We searched all records in the CAGR coded as 'asthma' using the following terms: ("cholinergic antagonists" or "anticholinergic" or "anti-cholinergic" or "cholinergic" or "muscarinic" or "antimuscarinic" or "ipratropium" or "tiotropium" or "atropine" or "atrovent" or "oxitropium" or "Sch1000" or "duovent", all as (textword) or (MeSH )) AND ("asthma" or "wheez" or "respiratory sounds" or "bronchial spasm", "bronchospas" or "bronch" or "spasm" or "bronchoconstrict" or "bronchoconstriction" or "bronch" or "constrict", all as (textword) or (MeSH )) AND ("adolescent" or "child" or "paediat" or "pediat" or "infan" or "toddler" or "bab" or "young" or "preschool" or "pre school" or "pre-school" or "newborn" or "new born" or "new-born" or "neo-nat" or "neonat", all as (textword) or (MeSH )).
We also conducted an additional search of CENTRAL (see Appendix 2). We searched all databases from their inception to April 2011 and we imposed no restriction on the language of publication.
Searching other resources
We checked reference lists of all primary studies and review articles for additional references.
Data collection and analysis
From the title, abstract, or descriptors, two review authors (LT and AC) independently reviewed literature searches to identify potentially relevant trials for full review. We conducted searches of bibliographies and texts to identify additional studies.
Selection of studies
From the full text, using specific criteria, two reviewers (LT and AC) independently selected trials for inclusion. We resolved disagreement by consensus.
Data extraction and management
LT and AC extracted data for the trials for the outcomes above. We combined all trials using Review Manager 5 (RevMan 2011).
Assessment of risk of bias in included studies
Two review authors (LT and AC) performed methodological quality assessment, using the 'risk of bias' tool described in the Cochrane Handbook of Systematic Reviews of Interventions (Higgins 2011), focusing on:
• random sequence generation;
• allocation concealment; and • blinding
We graded each domain as either 'high', 'low' or 'unclear' risk of bias.
Measures of treatment effect
We obtained all outcomes directly from the publications of the included studies.
Continuous Outcomes
For continuous outcomes measured on the same metrics, we calculated individual and pooled statistics as weighted mean differences (WMDs) with 95% confidence intervals (CIs). For continuous outcomes measured on different metrics, we combined data with a standardised mean difference (SMD).
Dichotomous Outcomes
For dichotomous variables, we calculated individual and pooled statistics as odds ratios (ORs) with 95% CIs.
Unit of analysis issues
None relevant.
Dealing with missing data
The review authors did not contact any study authors as it was not felt necessary and the studies were also not recent.
Assessment of heterogeneity
We initially pooled all data with a fixed-effect model. We measured heterogeneity using the I 2 statistic (a measure of the degree of inconsistency between pooled studies). We used a random-effects model to determine the impact of the variation in the results on the overall effect estimate.
Assessment of reporting biases
We planned to investigate publication bias by visually inspecting a funnel plot if ten or more trials had been included in a single meta-analysis.
Data synthesis
We grouped outcomes relating to studies according to: 1. anticholinergic agents versus beta 2 -agonists; and 2. anticholinergic agents versus combination of anticholinergic agents plus beta 2 -agonists. We pooled outcomes that were reported in the studies when possible, in accordance with primary and secondary outcomes.
Subgroup analysis and investigation of heterogeneity
We examined the influence of trial characteristics on the observed treatment effect. Assuming sufficient numbers of trials and the availability of necessary data, we described clinical heterogeneity with respect to treatment setting and asthma severity.
• Age: two to five years versus five to eighteen years.
• Co-interventions: with corticosteroids versus none.
• Different delivery methods of anticholinergics: metered dose inhaler (MDI) versus nebuliser.
• Duration of anticholinergics administration: less than seven days versus more than seven days duration.
• Asthma severity: mild and moderate versus severe asthma.
Sensitivity analysis
Sensitivity analyses provide an approach for testing how robust the results of a review are relative to key decisions and assumptions that have been made in the process of conducting the review. We planned to investigate the overall study quality of the pooled result using the Cochrane approach.
R E S U L T S Description of studies
Results of the search are summarised below.
Results of the search
Of the 349 abstracts that we identified, we retrieved 81 papers for full assessment by the reviewers (LT and AC 
Included studies
Study design
All studies were randomised and double-blind except Ni 2003. All studies were of a parallel group design.
Participants
The included studies involved children between the ages of two and eighteen years who were treated for acute asthma. These studies recruited patients mainly from the emergency room (Cook 1985; Guill 1987 
Measurements of outcomes
Outcomes measured differed between the studies. For an overview of the outcomes measured in the studies, please see Table 1 . Definition of treatment failure varied between the studies. Guill 1987 considered three criteria for treatment failure (return visit to the emergency department within 12 to 24 hours; intravenous (IV) treatment; or admission to hospital 
Excluded studies
We excluded studies that focused on adult patients or that did not use inhaled anticholinergics as single agents for comparison (see Characteristics of excluded studies for reasons for exclusion).
Risk of bias in included studies
Our judgement on the risk of bias for included studies is summarised in Figure 1 . 
Allocation
We judged two studies to be at low risk of bias for random sequence generation (Guill 1987; Van Bever 1994). The randomisation method was less well described in four studies and we therefore judged them to be at unclear risk of bias (Cook 1985; Watson 1988; Calvo 1998; Ni 2003).
Blinding
We judged four studies to be at low risk of bias for blinding (Cook 1985; Guill 1987 ; Van Bever 1994; Calvo 1998), while we were unclear about the risk of bias in Watson 1988 and we judged Ni 2003 to be at high risk of bias. Calvo 1998: Blinding and randomisation were referred to, but were not described. Participants were excluded from study entry if they required hospitalisation. No participants failed treatment and all were accounted for. The addition of salbutamol and/or oral steroids may have influenced the response to therapy across the three groups. Cook 1985: This study is described as a double-blind trial although the method of double-blinding is not explicit. Three patients (one from each group) required IV therapy and did not complete the trial. Children of various age groups received different volumes of the medicines in their respective groups, however, there is no explanation of how this was done with the blinding intact. Guill 1987: This study is described as a double-blind trial. Randomisation was done for each episode of wheezing, rather than for individual patients. Although the method of double-blinding is explicit, it is difficult to explain how blinding was preserved when subjects entered into the trial more than once and yet did not receive the same treatment more than once. Ten episodes of wheezing were classified as treatment failure, six of these were in the group which received atropine sulfate only. Ni 2003: This study is an unblinded trial. No patients withdrew or dropped out. This paper was published in Chinese and translated. Van Bever 1994: This study is described as a double-blind trial. Medications were administered from blinded metered dose inhalers. Withdrawals were not reported.
Watson 1988: This study is described as a double-blind trial although the method of randomisation is not mentioned. No patients withdrew from the study because of the need for an additional bronchodilator. Two children were admitted to hospital at the end of the study because of failure to achieve a clinically significant improvement. These patients were in the group which received ipratropium bromide only.
Incomplete outcome data
Guill 1987 reported ten episodes of wheezing that were classified as treatment failure (two in the group which received metaproterenol only, six in the group which received atropine sulfate only and two in the group which received combination treatment). One study (Cook 1985) reported that three patients (one from each group) required IV therapy and did not complete the trial and hence we excluded the results of these patients from the analysis. Withdrawals were not reported in Van Bever 1994's study. No detailed description was available for outcome measures in one study which was published in Chinese and translated; but no patients withdrew or dropped out (Ni 2003).
Selective reporting
Outcomes measured differed between the studies. Outcome measures in each individual study were reported. One study (Ni 2003) reported outcome measures as "no symptoms" or "improved symptoms" (shortness of breath, wheeze and hypoxia); no detailed description was available for outcome measures. Ni 2003 reported complete improvement in symptoms in 40 children and partial improvement in symptoms in 22 children in the group treated with salbutamol in combination with ipratropium bromide. However, only 55 children were allocated to this group. This paper was published in Chinese and translated.
Other potential sources of bias
One study (Watson 1988 ) was supported by a grant from a pharmaceutical company. Two studies (Guill 1987; Van Bever 1994) received pharmaceutical company support for the medications.
Effects of interventions
Only data for anticholinergics versus beta 2 -agonists and anticholinergics versus anticholinergics plus beta 2 -agonists were available. We entered relevant data into forest plots but were only able to pool data for the outcomes of treatment failure and hospitalisation. We could not pool other data due to divergent outcome measurements, and different types of anticholinergic agents and bronchodilators used in the studies. Results are presented according to comparison and then by outcome, with the primary outcome listed first.
Anticholinergic agents versus beta 2 -agonists
We were able to include all six studies ( There is variability in the definition of 'treatment failure', although all required additional treatment. One study reported admission data discreetly from treatment failure data (Watson 1988). The other four studies reported data on treatment failure according to their own pre-defined criteria (see Table 1 ). In one study (Calvo 1998), we considered treatment failure as those children who were poor responders to bronchodilator therapy (PEF + 4% or less Calvo 1998 reported data on TAL score from eight measurements over two hours. We only extracted data for the first 30 minutes due to concerns arising over the addition of a known bronchodilator if there was a lack of improvement after 30 minutes. For results taken up to 30 minutes for the three treatment groups, please see Table 2 . Significant differences were observed at 15 and 30 minutes for salbutamol versus ipratropium bromide (at 30 minutes: 3.3 (standard deviation (SD) 1.1) versus 4.2 (SD 0.9); P < 0.01).
Cook 1985 measured symptoms on an in-house symptom score (see Table 1 ). No significant difference was reported between the treatment groups across the two hours of treatment on clinical rating.
Secondary outcome: requirement for additional medication
Calvo 1998, Cook 1985 and Guill 1987 measured the requirement for additional treatment in different ways (see Table 1 ). Calvo 1998 reported no significant difference in the requirement for additional study medication between children on ipratropium and those on salbutamol (5.3 (SD 1.1) versus 4.7 (SD 1.2); P > 0.05) respectively. Furthermore, there was no significant difference in the requirement for corticosteroids at 60 minutes between children on ipratropium and those on salbutamol (0.3 (SD 0.4) versus 0.2 (SD 0.4) respectively; P > 0.05). There was a significant difference in terms of need for additional bronchodilators in the ipratropium group compared with salbutamol (1.7 (SD 2.1) versus 1.0 (SD 1.8); P < 0.05). Cook 1985 reported the number of repeat nebulisations required.
No statistically significant differences were observed between treatment groups. Guill 1987 reported the number of treatments required. More participants in the metaproterenol group (7/15) could be discharged after fewer treatments than those in the atropine group (4/13). No P value was reported for the metaproterenol group versus the atropine group.
Secondary outcome: lung function
Data are presented by outcome (PEF and FEV 1 ) and then by study.
We have extracted and presented data for outcome assessment at 30 and 120 minutes where possible. We consider these time-points to be the most clinically relevant in an asthma attack. P values are presented from the published papers; some of these considered data at all time-points.
PEF (percentage predicted)
Calvo 1998 reported no significant difference between salbutamol (80.5 (SD 7)) and ipratropium (78.1 (SD 7.3)); P > 0.05 at 30 minutes (Analysis 1.3). We did not extract subsequent data due to the potential for confounding by the introduction of concomitant therapy in all groups. Guill 1987 reported lung function at 20 to 30 minutes after treatments were administered. We extracted data for lung function taken after the first administration which corresponds approximately to 30 minute data. We did not observe any significant differences between the groups at 30 (Analysis 1.3) minutes. We did not include data extracted for subsequent lung function measurement in the review as they represented assessment 20 to 30 minutes after a second treatment, and 40 to 60 minutes after the first treatment. 
Secondary outcome: pulse oximetry
Watson 1988 reported that there was no significant difference between the two groups for pulse oximetry. However, there was a significant improvement in oxygen saturation in the fenoterol group at 30 minutes which continued throughout the study (no P value reported). The improvement in oxygen saturation for ipratropium alone was not statistically significant at 30 minutes, but was so at 60 minutes and thereafter (no P values reported). Four studies reported data on treatment failure according to their own pre-defined criteria (see Table 1 ). In one study (Calvo 1998), we considered treatment failure as those children who were poor responders to bronchodilator therapy (PEF + 4% or less Table 2 . Significant differences were observed at 15 and 30 minutes for combination therapy versus ipratropium (at 30 minutes 2.8 (SD 1.0) versus 4.2 (SD 0.9); P < 0.01). Cook 1985 measured symptoms on an in-house symptom score (see Table 1 ). No difference was reported between the treatment groups across the two hours of treatment on clinical rating.
Secondary outcome: requirement for additional medication
Calvo 1998, Cook 1985 and Guill 1987 measured the requirement for additional treatment in different ways (see Table 1 ). Calvo 1998 reported a significant difference between combination therapy and ipratropium in terms of study medication requirement (3.7 (SD 1.1) versus 5.3 (SD 1.1) respectively; P < 0.01) and bronchodilator requirement (0.5 (SD 1.3) versus 1.7 (SD 2.1) respectively; P < 0.01). There was a non-significant difference between combination and ipratropium in terms of corticosteroid requirement (0.1 (SD 0.3) versus 0.3 (SD 0.4) respectively; P >0.05). Cook 1985 reported the number of repeat nebulisations required.
No statistically significant differences were observed between treatment groups. Guill 1987 reported the number of treatments required. More participants in the metaproterenol and combination groups could be discharged after fewer treatments than those in the atropine group (atropine group 4/13; combination group 5/ 16). No P values were reported for the combination group versus atropine group.
Secondary outcome: lung function
PEF (percentage predicted)
Two studies (Guill 1987; Calvo 1998) reported PEF percentage predicted. Calvo 1998 reported a significant difference between the combination (85.1 (SD 6.7)) and ipratropium groups (78.1 (SD 7.3)); P < 0.01 at 30 minutes (Analysis 2.4). We did not extract subsequent data due to the potential for confounding by the introduction of concomitant therapy in all groups. Guill 1987 reported lung function at 20 to 30 minutes after treatments were administered. We extracted data for lung function taken after the first administration which corresponds approximately to 30 minute data. No significant differences were observed between the groups. We did not include data extracted for subsequent lung function measurement in the review as they represented assessment 20 to 30 minutes after a second treatment, and 40 to 60 minutes after the first treatment.
FEV 1
Watson 1988 reported a significant difference between combination and ipratropium alone in terms of absolute change, (P = 0.005, all time-points), change in percentage predicted (P = 0.0002, all time-points; Analysis 2.6) and percentage change from baseline (P = 0.002, all time-points). All data were presented graphically. Absolute scores at 30 minutes were: combination group 1.94 (SD 0.93) and ipratropium group 1.51 (SD 0.84) (Analysis 2.6). Absolute scores at 120 minutes were: combination group 2.11 (SD 1.05) and ipratropium group 1.48 (SD 0.8) (Analysis 2.7).
FEF 25−75
One study (Watson 1988) reported this. A significant difference in FEF 25−75 was reported between the combination and ipratropium group (P < 0.005, no time-point specified). Absolute scores at 30 minutes were: combination group 1.57 (SEM: 0.25) and ipratropium group: 0.92 (SEM 0.15). Absolute scores at 120 minutes were: combination group 1.82 (SEM: 0.3) and ipratropium group: 0.94 (SEM 0.13).
Secondary outcome: pulse oximetry
Watson 1988 reported that there were no significant differences between the three groups. However, there was a significant improvement in oxygen saturation in the combination and fenoterol groups at 30 minutes which continued throughout the study (no P values reported). All studies reported no significant differences in side effects between the participants.
D I S C U S S I O N
In this review, we evaluated the trials that studied the efficacy of ipratropium bromide given alone or in combination with beta 2 -agonists (compared to a control of beta 2 -agonists) for acute asthma in children aged over two years. Despite an extensive and thorough literature search in which we found hundreds of papers examining anticholinergic drugs, only seven studies (one paper was an abstract from a conference proceedings of a paper (Van Bever 1994)) from six trials met the inclusion criteria for the review.
Summary of main results
We found that inhaled anticholinergic agents as single agent bronchodilators were less efficacious (i.e. led to more treatment failure) than beta 2 -agonists in children over the age of two years with acute asthma exacerbations. Anticholinergics were also less efficacious (i.e. led to more treatment failure) than anticholinergics combined with beta 2 -agonists. In this review, data on clinical scores/symptoms that were measured on different scales were variable but all generally showed that ipratropium bromide used alone was less efficacious compared to beta 2 -agonists or combined with beta 2 -agonists. Also, individual trials reported that lung function was superior in the combination group when compared to anticholinergic agents. In our review, there was no significant increase in the occurrence of tachycardia, tremor, mydriasis or dryness of oral mucous membranes observed among participants treated with anticholinergic agents. Ipratropium bromide has no or very little systemic toxicity. Another significant advantage to ipratropium bromide in the critically ill asthma patient is the lack of increase in heart rate, which does occur with beta 2 -agonist use (Cugell 1986). The only remarkable reported side effect in the literature is the inhibition of salivary secretions at high doses. When nebulised, ipratropium is very unlikely to affect urinary flow or intraocular tension, and possible effects on the eye (i.e. glaucoma) can be prevented by using a mouthpiece during nebulisation. Although data is not available in children, the speed of onset of effect is reported in adults with airway disease to be 3 to 30 minutes with up to 50% of the response occurring in three minutes and 80% in 30 minutes, with a peak bronchodilator effect observed within one to two hours, and duration of action of up to approximately six hours (Gross 1988).
Overall completeness and applicability of evidence
Our thorough systematic search for published and unpublished trials resulted in identification of important trials. We could only extract data from six trials. Despite the small number of studies, we conclude from the studies that inhaled anticholinergic drugs as single agent bronchodilators were less efficacious than beta 2 -agonists and anticholinergics combined with beta 2 -agonists.
Quality of the evidence
This systematic review was limited by the quality of existing data. In addition, there was clinical heterogeneity amongst the trials and we could not pool some data due to divergent outcome measurements and different types of anticholinergic agents and bronchodilators used in the studies. The number (i.e. six trials) and size of studies pooled were small. There were limited data on hospital admissions.
Potential biases in the review process
The studies were generally small with potential risk of bias as shown in Figure 1 .
Agreements and disagreements with other studies or reviews
Inhaled anticholinergics in combination with beta 2 -agonists is now the standard recommended treatment for children with acute moderate to severe asthma exacerbations.
A U T H O R S ' C O N C L U S I O N S Implications for practice
In children over the age of two years with acute asthma exacerbations, inhaled anticholinergic drugs as single agent bronchodilators were less efficacious than beta 2 -agonists. Inhaled anticholinergics on their own were also less efficacious than anticholinergics combined with beta 2 -agonists. Thus in children over the age of two years with acute asthma exacerbations, inhaled anticholinergics alone are not appropriate as a single agent. None of the major asthma guidelines currently recommend inhaled anticholinergics as a single agent and our review supports this. The use of anticholinergics was not found to be associated with significant side effects such as tachycardia, tremor, mydriasis or dryness of oral mucous membranes.
Implications for research
Inhaled anticholinergics combined with beta 2 -agonists is now the standard recommended treatment in guidelines for children with acute moderate to severe asthma exacerbations. Thus, in light of our conclusion above, we do not recommend any further trials comparing inhaled anticholinergics as a single agent in children with acute asthma exacerbations.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Calvo 1998
Methods Randomised, double-blind parallel group trial. Method of randomisation not reported Outpatient Setting Participants N = 120 (Group 1: 40; Group 2: 40; Group 3: 40). 73 M/47 F. Mean age 7.3 years (age range: 5 to 14 years). No withdrawals occurred and all participants were accounted for • Inclusion criteria: age between 5 and 14 years; acute asthma attack; aerochamber well used; able to use peak flow meter; PEF < 80% predicted; TAL score > 0 on 5-point scale.
• Exclusion criteria: cardiac failure; lung disease; need for hospitalisation; first acute episode of acute bronchial obstruction; hypersensitivity to trial medications; treatment < 8 hours prior to study entry
Interventions
All treatments were administered by aerochamber • Group 1: ipratoprium bromide (0.025%) 1 mL i.e. 250 mcg (1 to 4 years); 1.5 mL i.e. 375 mcg (5 to 8 years); 2 mL i.e. 500 mcg (9 to 12 years)
• Group 2: fenoterol (0.5%) 0.125 mL i.e. 625 mcg (1 to 4 years); 0.25 mL i.e. 1250 mcg (5 to 8 years); 0.5 mL i.e. 2500 mcg (9 to 12 years)
• Group 3: ipratropium bromide + fenoterol (same dosage as above) Duration 2 hours. Repeat nebulisations at 2-hourly intervals until stable enough to return to inhaled or oral medication
Outcomes
Repeat nebulisation; pulse rate; respiratory rate; clinical rating of wheeze; air entry; respiratory distress; overall index of response to treatment Notes Plotnick and Ducharme contacted trialists and established that allocation concealment was adequate Different volumes of trial medication were given according to age of the participants in each treatment group. The trial was described as 'double-blind' and it was not reported how the blinding of the trialists to the treatment was maintained Interventions All treatments were administered via a Hudson 1700 updraft nebuliser and paediatric face mask attached with standard oxygen tubing to a Pulmo-Aid compressor • Group 1: metaproterenol 5% (50,000 mcg/mL), 0.2 mL (10,000 mcg) in < 12 years; 0.3 mL (15,000 mcg) ≥ 12 years in 2 mL normal saline
Risk of bias
• Group 2: atropine sulfate 0.05 to 0.1 mg/kg, max 2.0 mg i.e. 500 to 1000 mcg/kg in 2 mL normal saline
• Group 3: metaproterenol + atropine sulfate (same dosage as above) Three doses of nebulised medicines were administered 20 to 30 minutes apart
Outcomes
• Severity of bronchospasm as assessed by a pulmonary index score (0 to 12) at entry and 20 minutes after each inhalation
• PEF measure at entry and at 20 minutes after each inhalation (in patients old enough to perform manoeuvre)
• Number of treatments and treatment failure Notes Computer generated random numbers were used for each episode rather than for individual patients • Exclusion criteria: not available Interventions All treatments were administered via a nebuliser • Group 1: salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) + ipratropium bromide (0.25 to1 mL i.e. 62.5 to 250 mcg) diluted to 2 mL with normal saline
Risk of bias
• Group 2: 0.5% salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) diluted to 2 mL with normal saline
• Group 3: 0.025% ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg) diluted to 2 mL with normal saline Nebulised medications were administered 2 to 4 times a day
Outcomes
No symptoms or improved symptoms (shortness of breath, wheeze and hypoxia) Notes Translated paper • Exclusion criteria: mild asthma or very severe acute asthma attack with actual or impending respiratory failure, known hypersensitivity to sympathomimetic or atropinic compounds, if patient had disorders other than asthma, allergic rhinitis, atopic dermatitis or prior use of an inhaled bronchodilator within 5 hours of study entry
Risk of bias
Bias
Interventions
• Group 1: ipratropium bromide 250 mcg + fenoterol hydrobromide 625 mcg diluted to 4 mL isotonic solution
• Group 2: fenoterol 625 mcg diluted to 4 mL isotonic solution • Group 3: ipratropium bromide 250 mcg diluted to 4 mL isotonic solution All treatments were administered via a Hudson nebuliser driven by 7 L/min of room air. Two doses of inhalations were given 60 minutes apart
Outcomes
Clinical scores at 30, 60, 90 and 120 min Oxygen saturation at 30, 60, 90 and 120 min Spirometry at 30, 60, 90 and 120 min and after nebulised salbutamol Medication side effects
Notes
No mention of the method of randomisation At end of study, albuterol 0.5% (5000 mcg/mL) (i.e. 0.02 mL/kg (100 mcg/kg)), max 1 mL (5000 mcg), diluted to 2 mL with normal saline) was administered in an open fashion to assess for possible additional bronchodilatation Heterogeneity: Chi 2 = 0.00, df = 1 (P = 0.98); I 2 =0.0%
Risk of bias
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi 2 = 0.00, df = 1 (P = 0.98), I 2 =0.0% ED: emergency department; FEF 25−75 : forced expiratory flow at the 25 to the 75% point of forced vital capacity; FEV 1 : forced expiratory volume in the first second; I/E ratio: inspiration/expiration ratio; IV: intravenous; PEF: peak expiratory flow; SE: side effects; TAL: a clinical scoring system based on several markers such as respiratory rate, wheezing and cyanosis (the scale runs from 0 to 12, where 12 indicates a very severe illness). 
